Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015;4(3):117-9.
doi: 10.2217/cns.15.7. Epub 2015 Apr 23.

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials

Enrico Franceschi  1 , Alba A Brandes
Affiliations
Editorial

The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials

Enrico Franceschi et al. CNS Oncol. 2015.
No abstract available

Keywords: bevacizumab; glioblastoma; survival.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Comment on

References

    1. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2008;27:740–745. - PMC - PubMed
    1. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009;27(28):4733–4740. - PubMed
    1. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled Phase 2 trial. Lancet Oncol. 2014;15(9):943–953. - PubMed
    1. Brandes A, Finocchiaro G, Zagonel V, et al. Randomized Phase II trial AVAREG (ML25739) with bevacizumab (BEV) or fotemustine (FTM) in recurrent GBM: final result from the randomized Phase II trial. Ann. Oncol. 2014;25(Suppl. 4):iv137.
    1. Brandes AA, Franceschi E, Gorlia T, et al. Appropriate end-points for right results in the age of antiangiogenic agents: future options for Phase II trials in patients with recurrent glioblastoma. Eur. J. Cancer. 2012;48(6):896–903. - PubMed

MeSH terms

Substances

LinkOut - more resources